Adaptive Biotechnologies Corporation (ADPT) Rose on Solid Results

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity market regained its strength in the second quarter, following initial volatility, with the S&P 500 Index rising 10.94%. The Bloomberg U.S. Aggregate Bond Index also surged 1.21% during the quarter. Aristotle Atlantic’s Focus Growth strategy returned 17.70% gross of fees (17.67% net of fees) in the quarter, underperforming the Russell 1000 Growth Index’s 17.84% total return. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.

In its second quarter 2025 investor letter, Aristotle Atlantic Focus Growth Strategy highlighted stocks such as Adaptive Biotechnologies Corporation (NASDAQ:ADPT). Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is a commercial-stage biotechnology company. The one-month return of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) was -3.19%, and its shares gained 145.48% of their value over the last 52 weeks. On July 21, 2025, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stock closed at $10.31 per share, with a market capitalization of $1.566 billion.

Aristotle Atlantic Focus Growth Strategy stated the following regarding Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in its second quarter 2025 investor letter:

"Adaptive Biotechnologies Corporation (NASDAQ:ADPT) contributed to relative performance in the second quarter following a better-than-expected first quarter earnings report, which showed solid across-the-board momentum in both clinical testing and biopharma testing volumes. Adaptive continues to make progress on growing average selling prices (ASPs) and reducing cash burn. Adaptive is also rolling out its test on electronic medical record platforms, which will simplify the workflow and increase test ordering, processing and reporting efficiency."

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 27 hedge fund portfolios held Adaptive Biotechnologies Corporation (NASDAQ:ADPT) at the end of the first quarter, which was 27 in the previous quarter. While we acknowledge the potential of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Adaptive Biotechnologies Corporation (NASDAQ:ADPT) and shared the list of worst aggressive growth stocks to buy according to short sellers. The fund shared in its Q1 2024, letter that Adaptive Biotechnologies’ strategic decision coupled with strong revenue growth and profitability targets, highlights its long-term potential. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.